Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib, erlotinib, and afatinib,are effective therapeutic agents against non-small cell lung cancer (NSCLC) with EGFR-activating mutations, such as the exon 19 deletion and the L858R point mutation [1]. Here, EGFR is linked to non-small cell lung carcinoma.